Our client is seeking clinical stage assets in development for any number of blood cancers (AML, CML, etc.).

Our client is especially interested in candidates which have failed in clinical studies, either for safety or efficacy reasons.

Our client has technologies and expertise which they believe can be applied to identify new indications or patient populations, thereby rescuing the clinical and commercial value of these candidates.

Contact us at info@lacertabio.com if you have a candidate which fits these criteria.